Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Operations: 2019-2024

Historic Cash from Operations for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$172.6 million.

  • Nurix Therapeutics' Cash from Operations fell 36.06% to -$57.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$230.4 million, marking a year-over-year decrease of 137.16%. This contributed to the annual value of -$172.6 million for FY2024, which is 112.11% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Cash from Operations of -$172.6 million as of FY2024, which was down 112.11% from -$81.4 million recorded in FY2023.
  • Nurix Therapeutics' 5-year Cash from Operations high stood at -$80,000 for FY2020, and its period low was -$172.6 million during FY2024.
  • In the last 3 years, Nurix Therapeutics' Cash from Operations had a median value of -$159.8 million in 2022 and averaged -$137.9 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash from Operations slumped by 105,356.25% in 2021, and later skyrocketed by 49.09% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Cash from Operations (Yearly) stood at -$80,000 in 2020, then crashed by 105,356.25% to -$84.4 million in 2021, then crashed by 89.42% to -$159.8 million in 2022, then surged by 49.09% to -$81.4 million in 2023, then tumbled by 112.11% to -$172.6 million in 2024.